Is your practice ready for 2019? Here are some Insights from Speakers of the 2019 Newport Beach Ortho Value-Based Care Conference

Lots is happening in the healthcare area and it’s clear that the orthopaedic fee-for-value space will continue to evolve in 2019. Here are some insights from three speakers the 3rd Interdisciplinary Conference on Orthopedic Value based Care taking place on January 18-20, 2018 in beautiful Newport Beach, California.

Alexander R. Vaccaro, MD, PhD, MBA

Richard H. Rothman Professor and Chairman of Orthopedic Surgery

President, Rothman Orthopedic Institute

  • Can you share your best advice for motivating your teams?

Make sure they clearly understand goals and objective of any initiatives and have the opportunity for feedback and buy in. Show that you care about them and their opinions, be humble, celebrate/ recognize/ reward small and large wins, roll up your sleeves.

  • How do you break the silos in your organization?

Communicate , Communicate, Communicate. Reward the Mngt team based on team goals/ targets so that it incentives to work “across lines/ departments”. Have each leader “walk in the other’s shoes” so they get a better understanding of the position, responsibilities, problems / issues, work product. Constantly motivate, meet as a leadership team often, teak the team to dinner/ drinks – get to   know each other personally.

  • OP Surgery is moving to the outpatient area; how do you get ready for it?

Develop OP ASC’s (we now have 8 – and will got up to 12-14 with Northern Jersey and NY). Larger OR’s and PACU bays ; risk assessment all patients for appropriateness of care, visit existing ASC’s that are performing Spine/ Joints on an OP basis. Define specific criteria for cases qualifying for OP ASC. Ensure that the OR’s are big enough.

 

AnnMargaret McCraw

Chief Executive Officer

Midlands Orthopaedics & Neurosurgery, PA

   What’s the best thing you’ve read lately?

The Ideal Team Player by Patrick Lencioni | What Customers Crave by Nicholas Webb | Start With Why by Simon Sinek (not a recent read, but my “go-to” leadership philosophy)

   How do you promote innovation within your organization? 

Promoting innovation is easier to do when you’re the only private ortho-neuro group left in your MSA of 750,000 people, and you’re surrounded by 45 hospital-employed orthopaedists and 11 hospital-employed neurosurgeons – our survival literally depends on it. We first disrupted our market in 2012 when BCBS SC began to cover outpatient joint replacements in our ASC. Soon after, we began adding spine procedures. The average cost-savings is 15k-$40k per total joint replacement based on the average claims paid by BCBS SC to 3 hospital systems in the area per their own Treatment Cost Estimator. This distinction as the lowest cost surgical provider for complex ortho/spine procedures coupled with excellent outcomes has become our identity. Of course, once you have disrupted a market, you must continue to innovate or be disrupted by the competitors who are always nipping at your heels. To continue thriving, the innovation cycle must become part of the organization’s culture.

   In the past 12 months, how have you adapted to new patient experience expectations in the age of consumerism? 

What Customers Crave by Nicholas Webb is a great resource for this issue. In the previous 12 months, we have focused on reducing the amount of information we’re collecting at the front desk to enhance the intake process; we have initiated an internalPAINLESS (Patients are in Need. Lead Employees Share Solutions.) campaign; and we are in the process of implementing a scheduling platform that will allow patients to self-schedule via an app by Q4 2018.

 

Scott Sigman, MD

Orthopedic Surgery

National Leader in Opioid Sparing Orthopedic Surgery

Orthopedic Surgical Associates

  How Do You Break Silos In Your Organization?

Specifically, within orthopedics with the use of more expensive non-opioid medications, we found that pharmacy silos give us severe limitation in the ability to use these medications at a number of hospitals across the country.  Our focus has been to try and carve out the use of these medications, so that insurance companies will pay for these medications outside of the typical DRG or payment for an individual surgery.  We did this specifically by lobbying congress as well as CMS, both in person in Washington, D.C. as well as through letter writing campaigns.  We were fortunate to hear that as of January 1st some of these changes will be implemented going forwards through CMS.

  In the past 12 months, how have you adapted to new patient experience expectations in the age of consumerism?

I am a huge believer in social media.  I have postings on Linkedin for my business

friends.  I am also on Facebook for my older population of patients as well as  Instagram for my younger population of patients.  I remain connected with my patients.  With these avenues, we can express the latest state of the art techniques that we are performing and in engaging patients directly, we have found that we have great success.

  Surgeries moving to the outpatient area.  How do you get ready for it?

This has been the natural progression for us in the opioid sparing space. We are now successfully operating on patients near opioid free, which opens up the realm of possibility for outpatient surgery for even more extensive operations such as  total hip and knee replacements as well as outpatient spine surgery.  The patient expectations as well as patient selection I think are paramount to make sure that you have the best chance of success for patient experience.

 

FOR MORE INFORMATION

 

 

VGI Medical Surpasses 5,000 SiJoin Implants Used Throughout the United States.

Largo, FL – VGI Medical is dedicated to creating the next generation of spinal implants and procedures to improve the quality of life for its patients. One of the disruptive technologies, SiJoin, that has been developed by VGI Medical has achieved a significant milestone of over 5,000 implants used in more than 1,750 surgical procedures throughout the United States.

The sacroiliac (SI) joint is well documented as a potential source for lower back pain (LBP) and it is estimated that SI joint pain affects 15-25% of patients suffering from LBP. A number of publications have found that SI joint degeneration is present in patients who had previously undergone lumbar fusion surgery and pregnancy related pelvic instability is a common and disabling problem.

SiJoin offers significant clinical advantages to the other technologies currently on the market such as:

  • Tried and True Fusion – The SiJoin procedure utilizes a tried and true method for achieving joint fusion by preparing the joint (decortication), stabilizing the joint via cortical allograft implants, and using bone graft material to enhance  fusion across the joint
  • Less risk – Compared to lateral based SI joint methods, the SiJoin procedure minimizes the risk of the neural complications due to the direct posterior approach
  • Flexibility – The surgeon can choose to use a minimally invasive surgery (MIS), mini-open, or an open approach all while allowing for direct visualization of the SI joint
  • Biomechanics – Biomechanical stabilization of SiJoin is equivalent to lateral rod systems by taking advantage of the “lever arm” concept
  • Revision – Due to its unique design and approach, SiJoin can be used to revise other SI joint fusion procedures
  • Economic advantages – Due to the straight forward and lean business model employed by VGI Medical, SiJoin offers significant advantages to the facility (Acute, Outpatient and ASC) compared to the competition.

VGI Medical was founded in 2007 based on an invention developed by Tov Vestgaarden, PhD. It has become a leader in bringing innovation to the market including VerteLoc, CerLoc, SiJoin and VerteLP. The VerteLoc and CerLoc systems are specifically designed to stabilize and fuse the facet joint by utilizing a unique patented dual geometric design to limit motion of the affected spinal segment. Applying the principles of this success, VGI Medical added SiJoin for Sacroiliac Fusion. VerteLP is one of the latest innovations offering an improved implant for lateral procedures featuring its proprietary Talon Technology.

“ While it is exciting to achieve the 5,000 implant milestone, of greater importance is the number of successful patient outcomes we have seen with SiJoin. It is especially rewarding to see the satisfaction of our surgeon customers and their patients after a successful SiJoin procedure. This milestone demonstrates that SiJoin is the ideal solution for both primary and revision SI cases.” said Tov Vestgaarden, founder and CEO of VGI Medical.

_______

About VGI Medical

VGI Medical is a disruptive force in the spinal implant industry by creating four unique technologies specifically designed to enhance patient outcomes and improve the overall surgeon experience. Our calling is to provide the ideal solution to each clinical challenge faced with the existing technologies on the market today. With over 12,500 implants used since our inception, our implants and instruments have been thoroughly tested with exceptional results.

 

Spine Surgeon Becomes First In Western Pennsylvania To Reintroduce Lumbar Artificial Disc

PITTSBURGH, PA, December 5, 2018 // — Dr. Jocelyn Idema, Orthopaedic Spine Surgeon at The Center for Disc Replacement Surgery at Advanced Orthopaedics and Rehabilitation (AOR), recently implanted Centinel Spine’s newest generation of the prodisc L lumbar artificial disc replacement.  The prodisc L® is a Total Disc Replacement (TDR) technology platform that offers a surgical alternative to spinal fusions. Patients usually suffer from a single level degenerated disc in the lower (lumbar) spine and this technology works to relieve pain while allowing the potential for motion at the diseased spinal segment. 

As lower spine treatments continue to make advancements through innovative technologies and motion preserving techniques, patients are seeking out alternatives to lumbar fusions.  The goal at The Center for Disc Replacement Surgery at AOR is to improve the motion and function of the spine while maintaining the highest quality and highest standards of care related to both surgical and non-surgical spine interventions through evidence based medicine practices.  “By using newer motion preserving techniques, spinal discs can help retain the forward-to-back, bending side-to-side, and turning left-to-right spinal motion you were intended to have.” says Dr. Idema.  “This in turn helps to reduce the wear and tear associated with your spine above and below the damaged area.”  “I can’t begin to describe how this newest generation of lumbar artificial discs will continue to be a game-changer for patients.” reports Dr. Idema after the procedure.  She further  continues  “I have been doing cervical (neck) artificial disc replacement for years with really high success rates but the lumbar artificial discs only recently are making a resurgence because of various limitations including insurance companies authorizing the procedures.”

Centinel Spine is currently the only company in the United States to offer both upper and lower spine Total Disc Replacement devices.  The prodisc I implant, the predecessor of the prodisc L implant, was first implanted in 1990. The prodisc L implant that is used today was introduced outside the United States in 1999. It was approved by the Food and Drug Administration (FDA) for use in the United States in August 2006.   A prodisc L IDE clinical study evaluated the prodisc L Total Disc Replacement surgery compared to spinal fusion surgery*. The study demonstrated that prodisc L surgery is a safe and effective alternative to fusion surgery* for qualified patients.

About Centinal Spine
From the foundation of knowledge gained from the long-term clinical success of its lumbar products, Centinel launched its cervical product in 2008. Today, Centinel Spine still embraces the pioneering culture from 1924.  In 2006, the FDA Approved the prodisc L—the 2nd U.S. Lumbar Total Disc Replacement device and in 2007, the  FDA approved the  prodisc C—the 1st Complete U.S. Cervical and Lumbar offering.

For more information, please visit www.centinelspine.com and connect on Twitter and Facebook.

Johnson & Johnson Announces $5 Billion Share Repurchase Program

NEW BRUNSWICK, N.J.Dec. 17, 2018 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today announced that the Board of Directors has authorized the repurchase of up to $5 billion of the company’s common stock.

“Based on our continued strong performance and, more importantly, the confidence we have in our business going forward, the Board of Directors and management team believe that the company’s shares are an attractive investment opportunity,” said Alex Gorsky, Chairman and Chief Executive Officer.  “Our strong cash flow enables us to simultaneously return value to shareholders through our regular quarterly dividend and share repurchases, while at the same time continuing to deploy capital that will further strengthen our robust enterprise pipeline and drive long-term growth.”

Repurchases may be made at management’s discretion from time to time on the open market or through privately negotiated transactions. The repurchase program has no time limit and may be suspended for periods or discontinued at any time.  Any shares acquired will be available for general corporate purposes. The company had approximately 2,683.2 million shares of common stock outstanding as of September 30, 2018.  The company does not expect to incur debt to fund the share repurchase program.

Johnson & Johnson reaffirms its full-year 2018 sales and adjusted earnings per share guidance of $81.0 to $81.4 billion and $8.13 to $8.18 per share, respectively.

About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to the company’s plans with respect to share repurchases, involving, among other things, uncertainties inherent in business and financial planning. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, market conditions; the possibility that the repurchase program may be suspended or discontinued; economic factors, such as interest rate and currency exchange rate fluctuations; uncertainty of commercial success for new and existing products; the ability of the company to successfully execute strategic plans; the impact of acquisitions and divestitures; significant adverse litigation or government action, including related to product liability claims; challenges and uncertainties inherent in new product development; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; changes to governmental laws and regulations and domestic and foreign health care reforms. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.govwww.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

SOURCE Johnson & Johnson

Related Links

http://www.jnj.com

Kuros Ends Transformational Year With First MagnetOs Sales, Lead Clinical Program on Track, and Successful Capital Raise

SCHLIEREN (ZURICH), Switzerland, Dec. 17, 2018 (GLOBE NEWSWIRE) — Kuros Biosciences (SIX: KURN) has completed a transformational year, having realized first sales of its MagnetOs bone graft substitute in the U.S. and Europe and raised capital to support the roll-out of MagnetOs, and fund the Phase II clinical trial of fibrin-PTH (KUR-113) in spinal fusion.

Kuros raised gross proceeds of CHF 16.1 million from a capital increase on December 13, which will enable it to advance its pipeline, in particular the Phase II clinical study of its proprietary KUR-113 product in spinal fusion, and to progress commercialization of MagnetOs in the U.S. and selected geographies in Europe.

The Phase II study of KUR-113 is scheduled to start enrolling patients in Q2 2019 with an anticipated interim readout by the second half of 2020.

The Kuros team has also been strengthened with two new appointments. Michael Grau joined as Chief Financial Officer, bringing extensive experience in corporate financing and auditing in private and public companies and a strong operational background. Pascal Longlade, M.D., joined as Chief Medical Officer, bringing more than 20 years international experience in clinical research and development with leading pharmaceutical, biotech and medical device companies.

Joost de Bruijn, Ph.D., Chief Executive Officer of Kuros, said: “We have made excellent progress on our new course in 2018 and have a strong team in place to take the company forward. The recent capital raise adds to those solid foundations and allows us to build on that success. The first sales of MagnetOs are a realization of the hard work and dedication the Kuros team has put in and we are now focusing on the commercial roll-out, which is proceeding well. On top of that, we are pushing on with the exciting Fibrin-PTH program. Largely de-risked in successful trauma trials, it targets an important medical need in spinal fusion, which represents a significant commercial opportunity.”

For further information, please contact:

Kuros Biosciences AG Investors & Media
Michael Grau Hans Herklots
Chief Financial Officer LifeSci Advisors, LLC
Tel +41 44 733 47 47 +41 79 598 7149
michael.grau@kurosbio.com hherklots@lifesciadvisors.com

About MagnetOs
MagnetOs promotes local bone formation equivalent to current gold standard, autograft. A substantial number of clinically relevant and predictive studies have demonstrated its equivalence to the current gold standard (patient’s own bone, which may not be available in sufficient quantities and/or involves morbidity, costs and pain associated with its harvesting from another healthy site of the patient’s body). MagnetOs is a bone graft comprising biphasic calcium phosphate with an advanced submicron surface topography that directs bone formation after implantation. With its unique submicron surface topography, MagnetOs preferentially directs early wound healing toward the bone-forming pathway, resulting in an osteoinductive claim in Europe. MagnetOs is available as granules and as a putty formulation.

US indications statement
MagnetOs is an implant intended to fill bony voids or gaps of the skeletal system, i.e., posterolateral spine. MagnetOs must be used with autograft as a bone graft extender in the posterolateral spine. These osseous defects may be surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure.

EU indications statement
MagnetOs is intended for use as bone void filler for voids and gaps that are not intrinsic to the stability of the bony structure. MagnetOs is indicated for use in the treatment of surgically created osseous defects or osseous defects resulting from traumatic injury to the bone. MagnetOs is intended to be packed into bony voids or gaps of the skeletal system (i.e. extremities, spine, cranial, mandible, maxilla and pelvis) and may be combined with autogenous bone. MagnetOs should not be used to treat large defects that in the surgeon’s opinion would fail to heal spontaneously. In load bearing situations, MagnetOs is to be used in conjunction with internal or external fixation devices.

About Kuros Biosciences AG
Kuros Biosciences (SIX:KURN) is focused on the development of innovative products for bone regeneration and is located in Schlieren (Zurich), Switzerland and Bilthoven, The Netherlands. Visit www.kurosbio.com for additional information on Kuros, its people, science and product pipeline.

Forward Looking Statements 
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

Conformis Announces Strategic Actions to Reach Profitability and Reduce Debt

BILLERICA, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants designed to fit each patient’s unique anatomy, today announced it is implementing steps to improve its overall business model, including the prioritization of certain product development opportunities, cost reduction initiatives with the optimization of sales, marketing and administrative expenses and a reduction of its workforce.  In connection with these cost-saving measures, Conformis also announced today the reduction of its debt facility from $30 million to $15 million.  Conformis is taking these strategic actions to strengthen its focus on specific areas of opportunity that it believes will enable it to achieve profitability in 2021.

“We are taking decisive actions to prioritize our highest-impact new product opportunities, our Conformis Hip System and our cementless Press Fit total knee, which we believe provide us an opportunity to build a stronger, more sustainable business. As a result of these actions, we believe we can achieve profitability in 2021,” said Mark Augusti, Chief Executive Officer, Conformis. “These actions included the difficult decision to part ways with many valued employees. On behalf of the entire Company, I thank these colleagues for their many contributions to the business.”

The immediate organization-wide actions include:

Expense Management

Conformis is now taking actions to leverage its improvements in gross margin, which began in the third quarter of 2017, by optimizing its overall operating expense structure. As a result, Conformis believes that the actions taken today will lead to a reduction in the use of cash by operating activities from approximately $10 million per quarter during 2018 to less than $4 million per quarter in 2019. These expense reductions are company-wide, impacting sales and marketing, research and development and general and administrative expenses.

New Product Development Opportunities

Conformis plans to continue to execute its new product development programs focusing on the Conformis Hip System, iTotal G3 and cementless Press Fit knee. In the second half of 2019, Conformis expects to achieve full commercial launch of its Conformis Hip System, as well as the limited commercial release of its iTotal G3 total knee. Conformis also remains on track to deliver the limited commercial release of its cementless knee offering in early 2020.

“We recently achieved our 100th total hip arthroplasty case at Conformis and remain very positive about the status and value proposition of our Conformis Hip System. One of our goals when identifying the cost reductions announced today was to insure that they do not affect our previously announced commitment and investment plans for full commercial launch of our Conformis Hip System in the second half of 2019,” said Mark Augusti. “Entering the $7 billion hip arthroplasty market remains a key growth opportunity and a priority for the Company.”

International Expansion

Recognizing demand for its custom orthopedic knee replacement implants outside the United States, Conformis has selectively identified opportunities to expand its distribution in certain international markets. The expansion into other international markets is intended to help offset the sales weakness the Company is experiencing in Germany.

Organizational Transformation

To create a more focused organization and better align internal resources with the Company’s strategic priorities, Conformis reduced its personnel base this week, resulting in a reduction of approximately 10% of its total workforce. As a result of this action, Conformis expects to incur employee severance charges and other exit costs of approximately $700,000 in the fourth quarter and generate annual personnel expense savings in excess of $4 million in 2019.

Debt Reduction and Restructuring

With the reduced need for capital and to create an improved capital structure, Conformis and Oxford Finance LLC have entered into an amendment to their current Loan and Security Agreement.  Under the amended agreement, the Company used cash on-hand to pay down $15 million of its $30 million debt facility, and thereby reduced the total debt outstanding to $15 million and the associated interest expense going forward. The amendment also adjusted certain financial covenants.

“We believe this new plan will help right-size the Company, significantly lowering our cash needs,” noted Paul Weiner, Chief Financial Officer. “When combined with the planned continuation of gross margin improvements, we believe we can achieve cash flow breakeven within the next three years.”

2019 Operating Expenses Commentary

The Company expects the following operating expenses for the full year 2019:

  • Sales and marketing expense of approximately $32 million. This represents a reduction of approximately $8 million over our estimated 2018 sales and marketing expense.
  • Research and development expense of approximately $16 million. This represents a reduction of approximately $1.5 million over our estimated 2018 research and development expense.
  • General and administrative expense of approximately $21 million. This represents a reduction of approximately $10 million over our estimated 2018 general and administrative expense.
  • Capital expenditure of approximately $3.5 million versus our estimated 2018 $4 million.
  • Cash used, excluding financing activities, of less than $16 million versus our estimated 2018 $38 million.

About Conformis, Inc.

Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient’s unique anatomy. Conformis offers a broad line of customized knee and hip implants and customized pre-sterilized, single-use instruments delivered in a single package to the hospital. In clinical studies, Conformis iTotal CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants.  Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover customized implants and customized patient-specific instrumentation for all major joints.

For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at http://ir.conformis.com/.

Cautionary Statement Regarding Forward-Looking Statements

Statements in this press release about our future expectations, plans and prospects, including statements about the anticipated timing of our product launches, and our financial position and results, ability to achieve profitability, total revenue, product revenue, gross margin, operations, operating expenses, and financing plans, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. We may not actually achieve the forecasts disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual financial results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including whether our cash resources will be sufficient to fund our continuing operations for the periods anticipated; risks related to our estimates and expectations regarding our revenue, gross margin, expenses, revenue growth and other results of operations; risks related to our impact of our reduction in force; risks associated with our ability or inability to satisfy loan covenants; and the other risks and uncertainties described in the “Risk Factors” sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

CONTACT:
Investor Relations
ir@conformis.com
(781) 374-5598

WishBone Medical, Inc. signs licensing agreement for the Guided Growth Plate

WARSAW, Ind., Dec. 14, 2018 (GLOBE NEWSWIRE) — WishBone Medical, Inc. has been granted a global, non-exclusive license for the sale of a patented guided growth plating system in children with deformed limbs.  These 3 patents were created and designed for the gradual correction of pediatric deformities in both the upper and lower extremities.

WishBone Medical is designing and developing its own guided growth plate and instrumentation systems in sterile packed, single use, disposable kits.  This product will come in both the 2-hole and 4-hole plates systems in multiple sizes as well as options in stainless steel and titanium.  The anticipated launch will be in first quarter 2019, following FDA Clearance.

Nick Deeter, Chairman of the Board WishBone Medical, said, “We are excited to enter into this license agreement of patented technologies to develop, produce and sell our guided growth systems.  These systems will provide global access in sterile packed, single use disposable kits for children who are suffering with these pediatric deformities around the world.”  Mr. Deeter added, “With this sterile packed system, we can go into hospitals and surgery centers that have not had access to the traditional reusable systems.”

Dr. Robert von Seggern, Executive Vice President at WishBone Medical, commented, “As a dedicated pediatric orthopedic company, WishBone Medical needed this product to round out its large portfolio of orthopedic implants designed specifically for children with orthopedic issues.”

About WishBone Medical, Inc.

WishBone Medical is a global pediatric orthopedic company, committed to providing anatomically appropriate innovative implants and instruments in sterile packed, single use, disposable kits, to prevent infection, reduce overall costs for our customers and achieve the best outcomes for children around the world who are still growing.  WishBone Medical currently has 42 pediatric orthopedic product systems with operations in Warsaw, IN, Istanbul, Turkey, and Singapore.

For further information, visit www.WishBoneMedical.com or call Mary Wetzel, Chief Operating Officer, at 574-306-4006.

Global $10.66 Bn Sports Medicine Devices Market Analysis and Forecasts 2017-2018 & 2025

Dublin, Dec. 13, 2018 (GLOBE NEWSWIRE) — The “Sports Medicine Devices Market to 2025 – Global Analysis and Forecasts By Product, Application, and Geography” report has been added to ResearchAndMarkets.com’s offering.

The global sports medicine devices market is expected to reach US$ 10,662.5 Mn in 2025 from US$ 5,822.6 Mn in 2017. The market is estimated to grow with a CAGR of 7.9% from 2018-2025.

The growth of the sports medicine devices market is primarily attributed to increasing incidence of sports injuries. Moreover, the presence of large number of sports medicine associations is expected to fuel the market growth. The introduction of advanced technology in the sports medicine market is expected to offer significant growth opportunity in the sports medicine devices market during the forecast period.

The innovations of the new technologies are expected to introduce new therapies and procedures that will help to reduce time and costs and provide optimized and personalized results to continue to shape the medical device industry. Also the intelligent orthopedics in combination with traditional techniques and high-end technology will enable to change the future of industry.

The associations for the sports medicine are increasing across the countries in the world. The associations are involved in spreading the awareness about the sport medicine which is helping sports players and athletes to recover from their injuries. Some of the global groups and associations for the sports medicine are International Council of Sports Science and Physical Education (ICSSPE), International Federation of Sports Medicine (FIMS) and World Federation of Athletic Training & Therapy (WFATT).

Global sports medicine devices market, based on product was segmented as, body reconstruction and repair, body support and accessories. In 2017, body reconstruction and repair segment held the largest share by the market, by product. This is mainly attributed to the benefits offered such as, reduction in pain and improved functioning. In addition, it also amplify the body’s natural healing abilities and enhances the growth of new cartilage, ligaments and tendons.

Global sports medicine devices market, based on application was segmented knee, shoulder, ankle/foot, elbow & wrist, and others. In 2017, knee segment held the largest share of market, by application. In addition, the segment is anticipated to witness a significant growth among other applications, during the forecast period.

Some of the major primary and secondary sources for sports medicine devices included in the report are World Health Organization (WHO), Organisation for Economic Co-operation (OECD), National Research Foundation (NRF), International Diabetes Federation (IDF), Canadian Institutes of Health Research (CIHR) and others.

Key Topics Covered:

1. Introduction 
1.1 Scope Of The Study
1.2 Research Report Guidance

2. Global Sports Medicine Devices Market – Key Takeaways 

3. Global Sports Medicine Devices- Market Landscape 
3.1 Overview
3.2 Market Segmentation
3.3 Pest Analysis

4. Global Sports Medicine Devices Market – Key Market Dynamics 
4.1 Key Market Drivers
4.1.1 Increase In The Number Of Sports Medicine Associations
4.1.2 Increasing Incidences Of Sports Injuries
4.1.3 Rising Demand For Minimally Invasive Methods
4.2 Key Market Opportunities
4.2.1 Penetration Into Emerging Economies
4.2.2 Introduction Of Advanced Technologies
4.3 Future Trends
4.3.1 Prevention Through Genomics
4.4 Impact Analysis

5. Sports Medicine Devices Market – Global Analysis 
5.1 Global Sports Medicine Devices Market Revenue Forecasts And Analysis
5.2 Global Sports Medicine Devices Market, By Geography – Forecasts And Analysis
5.3 Performance Of Key Players
5.3.1 Arthrex Inc.
5.3.2 Smith And Nephew
5.4 Expert Opinions

6. Global Sports Medicine Devices Market Analysis – By Product 
6.1 Overview
6.2 Global Sports Medicine Devices Market, By Product, 2017 & 2025 (%)
6.3 Body Reconstruction And Repair Market
6.3.1 Overview
6.3.2 Global Body Reconstruction And Repair Market Revenue And Forecasts To 2025 (US$ Mn)
6.3.3 Fracture And Ligament Repair Devices Market
6.3.4 Orthobiologics Market
6.3.5 Arthroscopy Devices Market
6.3.6 Prosthetic Market
6.4 Body Support Market
6.4.1 Overview
6.4.2 Global Body Support Market Revenue And Forecasts To 2025 (US$ Mn)
6.4.3 Braces Market
6.4.4 Topical Pain Relief Market
6.4.5 Compression Clothing Market
6.4.6 Thermal Therapy Devices Market
6.4.7 Others Market
6.5 Accessories Market

7. Global Sports Medicine Devices Market Analysis – By Application 
7.1 Overview
7.2 Global Sports Medicine Devices Market, By Application, 2017 & 2025 (%)
7.3 Elbow & Wrist Market
7.4 Shoulder Market
7.5 Knee Market
7.6 Ankle/Foot Market
7.7 Others Market

8. North America Sports Medicine Devices Market Revenue And Forecasts To 2025 

9. Europe Sports Medicine Devices Market Revenue And Forecasts To 2025 

10. Asia-Pacific Sports Medicine Devices Market Revenue And Forecasts To 2025 

11. Middle East & Africa Sports Medicine Devices Market Revenue And Forecasts To 2025

12. South And Central America Sports Medicine Devices Market Revenue And Forecasts To 2025 

13. Sports Medicine Devices Market – Industry Landscape 
13.1 Overview
13.2 Growth Strategies In The Sports Medicine Devices Market, 2015-2018
13.3 Organic Growth Strategies
13.3.1 Overview
13.3.2 Product Launches
13.3.3 Expansion
13.4 Inorganic Growth Strategies
13.4.1 Overview
13.4.2 Partnership
13.4.3 Acquisitions

14. Sports Medicine Devices Market, Key Company Profiles 

  • DJO Global
  • Zimmer Biomet
  • STRYKER
  • Smith & Nephew
  • DePuy Synthes
  • Wright Medical Group N.V.
  • Arthrex, Inc.
  • CONMED Corporation
  • Mueller Sports Medicine, Inc.
  • RTI Surgical, Inc.

For more information about this report visit https://www.researchandmarkets.com/research/7q4x59/global_10_66_bn?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Sports Medicine and Physiotherapy

OrthoPediatrics Corp. Announces Full-Scale U.S. Launch of Small Stature Scoliosis System

WARSAW, Ind., Dec. 13, 2018 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (NASDAQ: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, announced today the full-scale U.S. launch of its 26th surgical system, the RESPONSE 4.5/5.0mm System following U.S. Food and Drug Administration (FDA) 510(k) clearance in October. The Company’s newest system represents a significant product expansion for physicians to treat complex scoliosis in smaller stature patients at a younger age.

The RESPONSE 4.5/5.0mm System, designed in collaboration with pediatric orthopedic surgeons, builds upon the successful implant and instrument technology of the RESPONSE 5.5/6.0mm System to expand the platform offering. The new small stature scoliosis system offers a hybrid implant technology allowing the option of either a 4.5mm rod in cobalt-chromium or 5.0mm rod in titanium or cobalt-chromium, multiple implant connector options, and innovative, new instrumentation.

Dr. Jonathan Phillips, Pediatric Orthopedic Surgeon & Associate Professor of Orthopedics at University of Central Florida, College of Medicine, served as a design surgeon for the small stature system and commented, “I am excited for the launch of the highly anticipated small stature RESPONSE system from the leader in children’s orthopedic technologies. Conceived to mesh seamlessly with the exceptionally successful RESPONSE system for larger statures, this instrumentation has been designed to serve a unique weight and size demographic in children’s orthopedics and extends the versatility of OrthoPediatrics’ spinal instrumentation options. I look forward to this radical improvement to care for a diverse cohort of the most underserved children.”

RESPONSE™ Spine System
Designed with a complete focus on children, the RESPONSE system offers a simple, technologically advanced system of instruments and implants to treat the distinct needs of pediatric patients with spinal deformities. The system features advanced instrument & implant technology including 1) innovative, low profile screw design including a proprietary set screw thread design for improved fixation and reduced potential for cross threading, and 2) unique pedicle screw head accepts multiple rod diameters in either cobalt chrome or titanium. Additionally, the system has versatile reduction & de-rotation capabilities with rod reducer instrument designed for easy snap on and off 2-in-1 rod reduction instrument enables each surgeon to perform reduction and de-rotation technique of choice and serves as a rod reducer and de-rotator in one.

About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on providing a comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 26 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This offering spans trauma & deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 38 countries outside the United States.

Investor Contacts
The Ruth Group
Tram Bui / Emma Poalillo
(646) 536-7035 / 7024
tbui@theruthgroup.com / epoalillo@theruthgroup.com

Overland Park Surgical Suites First Outpatient Surgery Center In Region To Offer Robotics-Assisted Partial And Total Knee Replacement Surgery Using The NAVIO™ Surgical System

OVERLAND PARK, Kan.Dec 13, 2018 /PRNewswire/ — Overland Park Surgical Suites is a state of the art outpatient surgical center and is the first outpatient surgery center in the Midwest to offer patients a robotics-assisted alternative to traditional knee replacement surgery.

“We were eager to bring the NAVIO robotics-assisted surgery to the area,” said Scott Abraham, M.D., Orthopedic Surgeon and founder of Overland Park Surgical Suites, LLC. “This exacting technique is the preferred approach for most patients and we’ve seen dramatic surgical outcomes.”

The NAVIO Surgical System starts with an advanced computer system that gathers precise anatomic and alignment information about a damaged knee that a surgeon uses to create a specific surgical plan, according to Dr. Abraham.

“This extra layer of data collection is designed to ensure the knee procedure is performed as accurately as possible for the best long-term outcome,” he said.

Abraham has already performed more than 100 robotic-assisted partial and total knee replacements at Overland Park Surgical Suites and St. Joseph Medical Center, and draws patients to his practice from throughout KansasMissouri and Iowa. He said the NAVIO System is particularly well suited for active adults in their 40s and 50s who have developed knee problems, but have opted to put off surgery as a remedy.

“Knee replacement surgery has a controversial reputation,” Abraham added.

Unfortunately, this leads many patients to delay medical intervention because of concerns about invasive surgery, painful rehab and significant downtime. The NAVIO System helps offset these concerns with the improved accuracy and the potential for faster recovery, leading to the goal of improved surgical outcomes and increased patient satisfaction.

The first knee implant procedure was performed 50 years ago in 1968, according to the American Academy of Orthopaedic Surgeons. Now, more than 600,000 knee replacement surgeries are performed each year, making it one of the most in-demand surgical specialties in the country. Yet often, patients are dissatisfied with the outcome.

Not so for Beth Archer of Leawood, who in October was the first person in the state of Kansas to undergo a partial knee replacement using robotic surgical assistance at Overland Park Surgical Suites.

“I’d been living with knee pain for four years,” Archer said. “The quality of my life dramatically improved with my partial knee replacement done with the NAVIO Surgical System. I returned home immediately and was self-sufficient, had little pain and within a week I was walking without a cane or walker. I highly recommend this robotic surgery.”

Abraham added that the NAVIO benefits are many, yet robotic surgical-assist is still in its infancy.

“We’re proud that Overland Park Surgical Suites is the first outpatient surgery center in the region to offer this state of the art NAVIO knee replacement procedure,” Abraham said. “But we won’t be the last. In fact, we think this is the future of the surgical field. It puts the power of robotics in the skilled hand of the surgeon. And that means a better outcome for all our patients.”

For more information or to schedule a NAVIO consultation with Dr. Abraham, call APEX ORTHOPEDICS and Sports Medicine at 913-642-0200.

NOTE: Not all patients are candidates for surgery using the NAVIO Surgical System. Discuss your condition and implant options with your surgeon. Individual results of joint replacement vary. Implants may not produce the same feel or function as your original knee. There are potential risks with knee replacement surgery such as loosening, fracture, dislocation, wear and infection that may result in the need for additional surgery. NAVIO is not for everyone. Children, pregnant women, patients who have mental or neuromuscular disorders that do not allow control of the knee joint, and morbidly obese patients should not undergo a NAVIO procedure.

(www.OverlandParkSS.com
Overland Park Surgical Suites is a state-of-the-art, orthopedic outpatient surgical center in Overland Park, KS. It was established by clinical personnel to offer safe, high quality surgical care. It is one of the first surgery centers in the Kansas City area to perform outpatient total joint replacements and is licensed by the State of Kansas and accredited by The Joint Commission.

About Smith & Nephew: 
(www.RediscoverYourGo.com
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people’s lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were more than $4.8 billion. Smith & Nephew is a member of the FTSE100.

TM is a Trademark of Smith & Nephew

Contact:      

Betsy Donnelly

Phone:         

913 208 5400

Email:           

Betsy@TrailheadMarketingTeam.com

SOURCE Overland Park Surgical Suites

Related Links

http://www.overlandparkss.com